Long Time Coming: Pediatric Gastroenterologists React to New Dupilumab EoE Approval

Following the January 25, 2024 approval of dupilumab for eosinophilic esophagitis in patients 1-11 years of age, a trio of pediatric gastroenterologists shares their thoughts on the new indication, their anticipated priority of use, and potential hurdles to optimal treatment uptake.

Related Keywords

Elizabeth Spencer ,Riha Bhatt ,Drug Administration ,Vanderbilt University Medical Center ,Icahn School Of Medicine At Mount Sinai ,Regeneron Pharmaceutical ,Biologics License Application ,Priority Review ,Icahn School ,Mount Sinai ,Mount Sinai Kravis Children ,Priority Review Application ,Pediatric Eosinophilic ,Dupilumab ,Dupixent ,Eosinophilic Esophagitis ,Gastroenterology ,